<DOC>
	<DOCNO>NCT00304460</DOCNO>
	<brief_summary>Background : -Although IL-2 shrink tumor 20 percent patient metastatic kidney cancer 15 percent patient metastatic melanoma , fully know drug work . Objectives : -To good understand IL-2 cause tumor shrink . Eligibility : -Patients 18 year age old metastatic kidney cancer metastatic melanoma Design : - 135 patient melanoma 110 patient kidney cancer may enrol . - Patients hospitalize 7 day treatment . They receive IL-2 intravenously ( vein ) 15 minute every 8 hour 4 day 12 dos . This constitute one treatment cycle . - Research blood sample collect daily first treatment cycle one two day follow last dose . - Patients may ask undergo leukapheresis , procedure collect large quantity white blood cell . This involve collect blood needle arm vein . The blood direct cell separator white cell extract . The rest blood ( red cell , platelet , plasma ) return patient needle needle arm . - About 7-10 day discharge hospital , patient return second treatment cycle without research blood sampling . - 2 month therapy , patient evaluate scan , x-ray , blood test evaluate tumor effect treatment immune cell . - Patients whose tumor shrink remain stable may continue treatment ( without repeat full set research blood sample ) long benefit treatment develop unacceptable side effect . Patients continue treatment evaluate every 2 month 3 4 time every 3 6 month .</brief_summary>
	<brief_title>Mechanism Action High-Dose IL-2 ( Aldesleukin ) Metastatic Melanoma Kidney Cancer</brief_title>
	<detailed_description>Background : - Although interleukin-2 ( IL-2 ) approve standard therapy US Food Drug Administration metastasis melanoma renal cell carcinoma , mechanism action patient population still completely understood . - Methods study regulatory T-cells measuring recently discover cytokine available early study IL-2 administration . Objectives : - Explore peripheral blood sample patient metastatic renal cell cancer melanoma receive high-dose IL-2 identify serum protein level lymphocyte phenotype may associate predictive tumor regression . Eligibility : - Patients metastatic renal cell cancer melanoma great equal 18 year age , ECOG 0 1 expect survival great three month . - Patients systemic infection , coagulation disorder , major medical illness cardiovascular , respiratory immune system exclude , include patient ejection fraction less 45 % FEV1 VC less equal 60 % predict . - Patients must prior therapy within 28 day , previous IL-2 therapy , pregnant , untreated clinically significant tumor involvement CNS major nerve compression , great 25 % estimate hepatic replacement . Design : - Aldesleukin 720,000 IU/kg intravenous bolus 15 minute every eight hour 12 dos administered cycle treatment . - Seven 10 day discharge , second cycle treatment administer . - 20 mLs blood serum 20 mLs blood peripheral blood cell collect daily first cycle aldesleukin administration day follow last dose . 20 mLs blood serum 50 mLs blood cell separation obtain day 2 4 follow completion IL-2 administration . On one day , additional 50 mLs blood cell separation 2 hour apheresis may substitute . - Approximately two month begin therapy , response assessment perform . - Patients stable regress disease receive second complete treatment course . Subsequent course may administer evidence on-going tumor regression without long-term irreversible toxicity . - In first 5 patient diagnosis ( metastatic renal cell cancer melanoma ) follow cytokine level assay : VEGF , CD40L , FASL , TRAIL , GRO-alpha , IP10 , GM-CSF , IFN-gamma , IFN-alpha , IL-1 , IL-5 , IL-6 , IL-8 , IL-10 , IL-12 , IL-13 , IL-15 , TNF-alpha , TNF-beta ; follow phenotypic marker study : CD3 , CD4 , CD8 , CD16 , CD25 , CD27 , CD28 , CD56 , CD80 , CD95 , CD107a , CD152 , FoxP3 , annexin V. - After first 10 patient analyzed , scope test narrow show response IL-2 . - Initially , total 127 evaluable patient melanoma enrol , presume 15 % response rate . With approval amendment F , new accrual ceiling 200 patient metastatic melanoma establish complete propose analysis . - A total 100 evaluable patient renal cell carcinoma enrol presumed 20 % response rate . - Allowing small number inevaluable patient , total 200 patient melanoma 110 patient renal cell carcinoma may enrol .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>INCLUSION CRITERIA : Any patient metastatic , measurable , histologicallyproven RCC melanoma candidate highdose IL2 therapy . Expected survival great three month . Age great equal to18 year old . ECOG le 2 . Serum creatinine less equal 1.4 mg/dl creatinine clearance great equal 90 mL/min , total bilirubin less equal 2.0 mg/dl , except patient Gilbert 's Syndrome must total bilirubin less 3.0 mg/dl . Platelet count great 100,000/mm ( 3 ) . Absolute neutrophil count great 1000/mm ( 3 ) . Serum ALT/AST less three time upper limit normal . Must willing sign durable power attorney . Must willing practice effective contraception ( regardless gender ) . Must willing sign inform consent document . EXCLUSION CRITERIA : Significant second malignancy within 3 year protocol entry likely require intervention year follow protocol entry . Significant psychiatric disease opinion Principal Investigator would prevent adequate inform consent render immunotherapy unsafe contraindicate . Requirement systemic inhale steroid administration ( topical therapy acceptable ) . Prior therapy within 28 day ( except focal radiation bone lesion ) . Systemic infection , coagulation disorder evidence active bleeding , major medical illness cardiovascular , respiratory immune system . ECOG performance status great 2 . Pregnancy . Previous IL2 therapy . Positive HIV antibody titer , Seropositive hepatitis B C antigen . FEV1 VC less equal 65 % predict ( pulmonary function screen do patient significant smoke history [ great 20pk/years ] suspicion pulmonary disease history examination ) . Abnormal stress cardiac exam ( do patient great equal 60 year old others indicate clinically ) active cardiac ischemia significantly abnormal EKG . Greater 25 % estimate hepatic replacement tumor SGOT SGPT great 3x normal . Untreated clinically significant ( i.e . size presence edema ) tumor involvement CNS major nerve compression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 27, 2014</verification_date>
	<keyword>Serum Protein Levels</keyword>
	<keyword>Lymphocyte Phenotypes</keyword>
	<keyword>Predictive Analysis</keyword>
	<keyword>Serum Cytokines</keyword>
	<keyword>Kidney Cancer</keyword>
	<keyword>Renal Cell Cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Metastatic Melanoma</keyword>
</DOC>